Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Non-small cell lung cancer (NSCLC) is a complex disease, and understanding its underlying genetic mutations is crucial for effective treatment. One significant subtype is ALK-positive NSCLC, which accounts for approximately 3-5% of all NSCLC cases. This specific genetic alteration, a rearrangement of the Anaplastic Lymphoma Kinase (ALK) gene, drives cancer cell growth and proliferation. Identifying this biomarker is the first step towards personalized medicine, opening the door to highly effective targeted therapies.
Historically, treatments for ALK-positive NSCLC have evolved, with the advent of tyrosine kinase inhibitors (TKIs). Early generations of ALK TKIs, such as crizotinib, showed promise but often faced challenges with acquired resistance and limited efficacy against brain metastases. This led to the development of second and third-generation TKIs, designed to overcome these limitations.
Among the most advanced options is lorlatinib, a third-generation ALK TKI. Lorlatinib's development was driven by the need for a drug that could effectively target a broad spectrum of ALK mutations, including those that confer resistance to earlier TKIs. Furthermore, its ability to efficiently cross the blood-brain barrier is a critical advantage, as brain metastases are a common and challenging manifestation of ALK-positive NSCLC. The superior progression-free survival (PFS) observed in clinical trials like the CROWN study underscores lorlatinib's enhanced efficacy.
The introduction of lorlatinib represents a significant advancement in the treatment of ALK-positive NSCLC. Its capacity to manage resistant mutations and its pronounced effect on intracranial disease position it as a vital therapeutic option for many patients. As research continues, understanding the specific role and optimal use of lorlatinib and other ALK inhibitors remains paramount in improving outcomes for individuals battling this disease. NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-quality pharmaceutical ingredients to support the development and availability of such life-saving treatments.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
